Novo Nordisk presents phase 3 data for next-generation amylin cagrilintide, leading to advancement into dedicated clinical programme US$ 27.05 Min. order: 1 piece ★★★★★ 4.6 (120 reviews) Sold : Login>>
Novo Nordisk shares higher on positive Phase 3 trial results for obesity drug Cagrilintide US$ 29.44 Min. order: 1 piece ★★★★★ 4.8 (241 reviews) Sold : Login>>
Novo Nordisk's experimental obesity drug CagriSema shows blood pressure benefits US$ 27.47 Min. order: 1 piece ★★★★★ 5.0 (198 reviews) Sold : Login>>